On May 22, 2023 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, reported that it will present new data evaluating the use and potential of its methylation-based multi-cancer early detection (MCED) platform at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, June 2-6 (Press release, Grail, MAY 22, 2023, View Source [SID1234631935]). Presentations include interim results from SYMPLIFY, the first large-scale prospective study to evaluate GRAIL’s MCED test in symptomatic patients referred for cancer suspicion, as well as Galleri real-world clinical surveillance data and subset analyses from the PATHFINDER clinical implementation study. An evaluation of Galleri implementation using a centralized model within Mercy’s multi-state health system will also be presented.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"If we hope to bend the cancer mortality curve, we need a new, population-scale approach for screening people that finds many more cancers than we do today, in earlier stages when treatments are often more effective," said Josh Ofman, MD, MSHS, president at GRAIL. "We believe that adding multi-cancer early detection testing to recommended screening is the best chance to address the growing burden of late-stage cancer in an aging population. We are excited to present new data at this year’s ASCO (Free ASCO Whitepaper) Annual Meeting supporting the use of GRAIL’s MCED technology in adults at elevated risk of cancer, as well as initial findings from SYMPLIFY, a study evaluating patients presenting with signs and symptoms who are referred for a cancer evaluation."
Initial results from SYMPLIFY will be presented during an oral session. SYMPLIFY is the first prospective study assessing the clinical performance of GRAIL’s MCED Methylation Platform in individuals with signs and symptoms that may indicate cancer. Researchers will also present an analysis of the early real-world clinical experience using the Galleri MCED test to detect a shared cancer signal and predict cancer signal of origin (CSO) to guide targeted diagnostic workup. Additionally, doctors from Mercy will present a preliminary analysis of an MCED test implementation model within a large health system utilizing a patient navigation system. A follow-up analysis to the PATHFINDER study assessing clinical implementation of the test following a cancer signal detected result and CSO-guided workups will also be presented. Results from the PATHFINDER study were previously reported during the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022.
Abstracts will be available on the 2023 ASCO (Free ASCO Whitepaper) Annual Meeting website. Updated analyses will be presented at the Annual Meeting.
Oral Sessions
Title: Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation
Session Title: Care Delivery and Regulatory Policy
Date/Time: June 3, 2023, 1:27 to 1:39 PM CDT
Location: S100a
Abstract Number: 1501
Title: Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date/Time: June 5, 2023, 9:12 to 9:24 AM CDT
Location: Hall D2
Abstract Number: 3004
Posters
Title: Early real-world (RW) experience with a multi-cancer early detection (MCED) test
Session Title: Prevention, Risk Reduction and Hereditary Cancer
Date/Time: June 3, 2023, poster session from 1:15 to 4:15 PM CDT; panel discussion from 5:04 to 5:14 PM CDT
Location: S102
Abstract Number: 10519
Title: Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing
Session Title: Prevention, Risk Reduction and Hereditary Cancer
Date/Time: June 3, 2023, poster session from 1:15 to 4:15 PM CDT; panel discussion from 5:04 to 5:14 PM CDT
Location: S102
Abstract Number: 10520
Title: Preclinical circulating tumor DNA (ctDNA) shedding duration and prognostic implications of modeling 3669 participants from American Cancer Society Cancer Prevention Study-3 (CPS-3) and Circulating Cell-free Genome Atlas substudy 3 (CCGA3)
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date/Time: June 3, 2023, 8:00 to 11:00 AM CDT
Location: Hall A
Abstract Number: 3060
Title: Elevated cancer risk among individuals with combinations of cancer-related risk factors: A large claims database analysis
Session Title: Prevention, Risk Reduction and Hereditary Cancer
Date/Time: June 3, 2023, 1:15 to 4:14 PM CDT
Location: Hall A
Abstract Number: 10561
Title: Examining the potential for lead-time bias by estimating stage-specific proportions of deaths due to diagnosed cancer
Session Title: Prevention, Risk Reduction and Hereditary Cancer
Date/Time: June 3, 2023, 1:15 to 4:15 PM CDT
Location: Hall A
Abstract Number: 10535
Title: Overall and non-lung cancer incidence in the National Lung Screening Trial (NLST) as indicators of potential for multi-cancer screening
Session Title: Prevention, Risk Reduction and Hereditary Cancer
Date/Time: June 3, 2023, 1:15 to 4:15 PM CDT
Location: Hall A
Abstract Number: 10633
Title: Methylation-based prediction of myelodysplastic syndrome survival outcomes
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes and Allotransplant
Date/Time: June 5, 2023, 8:00 to 11:00 AM CDT
Location: Hall A
Abstract Number: 7058
Title: Implementation of a multi-cancer early detection (MCED) test using a centralized model within (w/i) a multi-state health system
Session Title: Care Delivery and Regulatory Policy
Date/Time: June 5, 2023, 1:15 to 4:15 PM CDT
Location: Hall A
Abstract Number: 1526